Wisconsin is currently home to 1281 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
NTX-301 in MDS/AML
NCT04167917
Recruiting
NTX-301 is a DNMT1 inhibitor. The drug is an oral drug with preclinical data that has shown preclinical anti-leukemic efficacy. This is the first clinical trial using NTX-301 in patients with myeloid malignancies.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
08/05/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
Register for Updates
Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer
NCT03936478
Recruiting
This trial will investigate a novel 3-fraction radiation regimen for participants undergoing breast-conserving therapy (BCT) for early breast cancer that will: 1) significantly reduce the duration of treatment and can be completed in one-week (5 working days) and 2) MRI-guided radiotherapy (MRIdian) would limit the volume of normal tissue radiated and therefore resultant toxicity. The hypothesis is that 3-fraction radiation therapy can be delivered safely without compromising the therapeutic rat... Read More
Gender:
FEMALE
Ages:
40 years and above
Trial Updated:
08/05/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Breast Cancer, DCIS, LCIS
Register for Updates
CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial
NCT03455725
Recruiting
Prospective, multi-center, 2:1 randomized (Treatment : Sham Control), sham-controlled, double-blinded trial to compare treatment using the CardiAMP cell therapy system to sham treatment Treatment Group: Subjects treated with aBMC using the CardiAMP cell therapy system Sham Control Group: Subjects treated with a Sham Treatment (no introduction of the Helix transendocardial delivery catheter, no administration of aBMC)
Gender:
ALL
Ages:
Between 21 years and 80 years
Trial Updated:
08/05/2024
Locations: University of Wisconsin Madison, Madison, Wisconsin
Conditions: Refractory Angina, Chronic Myocardial Ischemia
Register for Updates
Validating a New Machine-Learned Accelerometer Algorithm Using Doubly Labeled Water
NCT05736302
Recruiting
The purpose of this study is to validate previously developed physical function-clustered specific machine-learned accelerometer algorithms to estimate total daily energy expenditure (TDEE) in individuals with general movement and functional limitations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/02/2024
Locations: University of Wisconsin-Milwaukee, Milwaukee, Wisconsin
Conditions: Movement Disorders, Energy Metabolism
Register for Updates
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
ALL
Ages:
31 years and below
Trial Updated:
08/02/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Neuroblastoma
Register for Updates
A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors
NCT03872947
Recruiting
The main purpose of this study is to establish the safety and the recommended dose of TRK-950 in combination with FOLFIRI, Gemcitabine / Cisplatin, Gemcitabine / Carboplatin, Ramucirumab / Paclitaxel, PD1 inhibitors (Nivolumab or Pembrolizumab), and Imiquimod Cream, Bevacizumab, Gemcitabine / Carboplatin / Bevacizumab, Pegylated liposomal doxorubicin (PLD), Carboplatin / PLD / Bevacizumab and Paclitaxel for selected advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/01/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Solid Tumor, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Colorectal Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Register for Updates
Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer
NCT06106477
Recruiting
This single-arm study is designed to test the hypothesis that a six-month intermittent fasting (IF) intervention is feasible for patients to adhere to and improves health-related quality of life while subjects are on adjuvant endocrine therapy (AET).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/31/2024
Locations: Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Breast Cancer
Register for Updates
Comparing Dosing Intervals of Nivolumab or Pembrolizumab in Locally Advanced or Metastatic Cancers
NCT04295863
Recruiting
A randomized research study of drugs nivolumab and pembrolizumab in patients with locally advanced or metastatic cancers. Based on data from earlier studies it appears that the drugs can be given less often then the currently approved schedule. This trial will compare drug levels from the blood from standard interval dosing levels versus taking the drugs less often.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/30/2024
Locations: SSM Health Cancer Care, Madison, Wisconsin
Conditions: Metastatic Cancer
Register for Updates
TRAQinform Assessment of Immunotherapy Response
NCT05819255
Recruiting
The intent of this study is to evaluate the actionable information output from the TRAQinform Immuno technology in a prospective, non-interventional clinical study. Subjects with metastatic melanoma treated with standard of care (SOC) dual-agent immunotherapy will be enrolled. Subjects will receive SOC immunotherapy monitored for treatment response with FDG PET/CT's at baseline (SOC), after 3-4 weeks of treatment (non-SOC) and 12 at weeks of treatment (SOC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin
Conditions: Melanoma
Register for Updates
A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease
NCT05804383
Recruiting
A Phase 1b Multiple Ascending Dose Study of the Safety and Tolerability of BMS-984923 in Healthy Older Adults and Patients with Alzheimer's Disease
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
07/29/2024
Locations: Spaulding Clinical Research, West Bend, Wisconsin
Conditions: Alzheimer's Disease
Register for Updates
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
NCT02675959
Recruiting
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibrotide prophylaxis for high-risk sickle cell or beta thalassemia patients undergoing a familial haploidentical allogeneic stem cell transplantation with CD34 enrichment and T-cell addback. This patient population historically has a risk of developing sinusoidal obstructive syndrome (SOS) and Defibrotide has demonstrated efficacy in treatment of SOS. The Funding Source is FDA OOPD... Read More
Gender:
ALL
Ages:
Between 6 months and 34 years
Trial Updated:
07/29/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Sickle Cell Disease
Register for Updates
Identifying Findings on Brain Scans That Could Help Make Better Predictions About Brain Cancer Progression, The GABLE Trial
NCT06319027
Recruiting
This phase II trial studies whether different imaging techniques can provide additional and more accurate information than the usual approach for assessing the activity of tumors in patients with newly diagnosed glioblastoma. The usual approach for this currently is magnetic resonance imaging (MRI). This study is trying to learn more about the meaning of changes in MRI scans after treatment, as while the appearance of some of these changes may reflect progressing tumor, some may be due the treat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2024
Locations: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Conditions: Glioblastoma, IDH-Wildtype
Register for Updates